
Hematologic Oncology
Latest News
Latest Videos

Podcasts
CME Content
More News

The phase 2 SANRECO trial met its primary end point, with 88% of this polycythemia vera population achieving a response with divesiran vs 19% with placebo.

Two pharmacy specialists discuss real-world data and clinical trial findings on the use of CAR T-cell therapy for pediatric patients with hematologic cancers.

Updated results from the phase 2 ELIANA trial support tisa-cel as definitive therapy for pediatric and young adult patients with relapsed/refractory B-ALL.

Pirtobrutinib plus venetoclax/rituximab reduced the risk of progression or death by 45% among those with CLL in the phase 3 BRUIN CLL-322 trial.

Transplant-associated thrombotic microangiopathy GVHD are related, but distinct consequences of endothelial injury after allogeneic HCT.

Clinicians “still don’t have the answer” on true toxicity thresholds, says Tiba Al Sagheer, PharmD, BCOP, BCACP, on CAR T-cell toxicity management.

Presenters at the 2026 National ICE-T Conference in Orlando, Florida, discuss the efficacy and safety of novel agents across hematologic disease states.

The world of cellular therapy is “still ever-expanding” as novel constructs continue to emerge, according to Megan Melody, MD.

The approval of Orca-T represents a “big advance” that must be studied further, according to Wendy Stock, MD.

The approval of Orca-T validates many years of work dedicated to manipulating the graft to improve outcomes among patients undergoing allogeneic transplant.

Orca-T is a “big advance” that must be studied further among patients with acute leukemias and myelodysplastic syndromes.

Whether Orca-T competes with post-transplant cyclophosphamide for GVHD prevention must be studied prospectively, said Wendy Stock, MD.

The FDA approval of Orca-T represents an “important advance” in the world of allogeneic transplant, according to Wendy Stock, MD.

Data from the phase 3 Precision-T trial support the FDA approval of allogeneic regulatory T-cell–based immunotherapy.

Julie M. Vose, MD, MBA, discussed how the digital age is impacting oncology care.

This year’s EHA Congress saw potential advances across multiple myeloma, leukemia, lymphoma, and other hematologic malignancy populations.

Updated phase 1/1b BGB-11417-101 trial data showed sonrotoclax 320 mg plus zanubrutinib achieved uMRD4 rates exceeding 90% in treatment-naive CLL/SLL.

























































